b'Bench-to-BedsideB2B URO-ONCOLOGY: GU CANCERS TRIAD MEETINGPRESENTING SPONSOR FROM 35,000FRIDAY, NOVEMBER 11 FROM 7:30-16:30 (CAN$50,666)Bench-to-bedside (B2B), or translational research, The B2B Uro-Oncology: GU Cancers Triad Meeting, has flourished in recent years, in response to the held in conjunction with the 42 ndCongress of the SIU, need for rapidly transferring laboratory breakthroughsoffers an ideal approach to review current clinical (from the bench) to the patient care setting (at theresearch advancements and their applications in bedside). Thus, a multi-faceted collaboration amonguro-oncology. This meeting will include a high-profile researchers, clinicians, and industry is fundamental ininternational faculty of experts in various disciplines, clinical studies in order to translate laboratory findingsproviding the opportunity to foster collaborative into clinically applicable therapeutics that may informdiscussions across specialties. new treatments, practices, and procedures. In this full-day session, held at the Palais des congrs B2B meetings offer an engaging way to learnde Montral, our expert faculty from around the world translational research and its applications in urology.will provide updates on the management of the three The multidisciplinary approach fosters an understandingmost prevalent urological cancers (prostate, bladder, across specialties. These meetings explore topics fromand kidney cancers) by emphasizing evolving trends basic research through to translation into real-worldin the early detection of disease, recent results of applications. The programmes can be customized clinical trials, new therapies, biomarkers, and novel to any urological condition and/or specific topictechnologies and treatment strategies, including new (diagnosis, treatment, etc.). The programmes aresurgical techniques. The programme will focus on available as one- or two-day live webcasts, or providing insights and sharing knowledge on best short-course capsules on SIU Academy. practices, aimed at guiding treatment decisions, and ultimately improving patient outcomes.Scientific Programme CommitteePeter Black, Canada (Chair)Alexandra Masson-Lecomte, FranceSimon Tanguay, CanadaDerya Tilki, GermanyExecutive Summary and Proposal availableupon requestNOVEMBER 913, 2022MONTREAL 23'